These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 15671919)

  • 21. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system.
    Cooper ME; Tikellis C; Thomas MC
    J Hypertens Suppl; 2006 Mar; 24(1):S57-63. PubMed ID: 16601575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The crosstalk between insulin and renin-angiotensin-aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention.
    Muscogiuri G; Chavez AO; Gastaldelli A; Perego L; Tripathy D; Saad MJ; Velloso L; Folli F
    Curr Vasc Pharmacol; 2008 Oct; 6(4):301-12. PubMed ID: 18855718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V; Buksa M; Loza V; Kulic M
    Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of diabetes in hypertensive patients: results and implications from the VALUE trial.
    Zhou MS; Schulman IH
    Vasc Health Risk Manag; 2009; 5(1):361-8. PubMed ID: 19475773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
    Boucek P
    Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV protease inhibitors activate the adipocyte renin angiotensin system.
    Boccara F; Auclair M; Cohen A; Lefèvre C; Prot M; Bastard JP; Capeau J; Caron-Debarle M
    Antivir Ther; 2010; 15(3):363-75. PubMed ID: 20516556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pathophysiological mechanisms of the renin-angiotensin system and its pharmacologic modification by ACE inhibitors or angiotensin II (type 1) receptor blockers in cardiovascular diseases].
    Huber K; Pachinger O; Pichler M; Klein W
    Z Kardiol; 1997 Apr; 86(4):239-50. PubMed ID: 9235795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renin inhibition--benefit beyond hypertension control.
    Kher V
    J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Target-organ protection with combination renin-angiotensin-system blockade.
    Prisantmd LM
    Clin Cardiol; 2009 Jan; 32(1):4-12. PubMed ID: 19142999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [How I treat... by optimizing the blockade of the renin-angiotensin-aldosterone system].
    Schleich F; Krzesinski JM; Piérard L; Scheen AJ
    Rev Med Liege; 2008 Apr; 63(4):174-81. PubMed ID: 18575070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of the pancreatic renin-angiotensin system in insulin resistance and the metabolic syndrome.
    Leung PS; de Gasparo M
    J Cardiometab Syndr; 2006; 1(3):197-203. PubMed ID: 17679833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system.
    Kurtz TW; Pravenec M
    J Hypertens; 2004 Dec; 22(12):2253-61. PubMed ID: 15614015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
    Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
    Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.
    Borghi C; ; Rossi F;
    High Blood Press Cardiovasc Prev; 2015 Dec; 22(4):429-44. PubMed ID: 26403596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angioedema related to Angiotensin inhibitors.
    Knecht SE; Dunn SP; Macaulay TE
    J Pharm Pract; 2014 Oct; 27(5):461-5. PubMed ID: 25124378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Adipose tissue renin-angiotensin system in obese].
    Yasue S; Ebihara K; Nakao K
    Nihon Rinsho; 2012 Sep; 70(9):1550-5. PubMed ID: 23012802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical studies on the blockade of the renin-angiotensin-aldosterone-system.
    Hennig L
    Clin Nephrol; 2003 Jul; 60 Suppl 1():S53-8. PubMed ID: 12940534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature.
    Hammoud RA; Vaccari CS; Nagamia SH; Khan BV
    Vasc Health Risk Manag; 2007; 3(6):937-45. PubMed ID: 18200812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.